HDAC9 and acute myeloid leukemia: In contrast to our previous observation in a cohort of relapsed/refractory AML patients where drug sensitivity profiles differed widely between patients in response to treatment with FDA-approved agents, our results showed a different pattern in response to treatment with the epigenetic library, where a few HDAC inhibitors displayed activity in all of the samples, irrespective of cytogenetic or molecular drivers.